ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 161 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2017. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $861 | +34.1% | 18 | 0.0% | 0.00% | – |
| Q3 2023 | $642 | -35.8% | 18 | +50.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 12 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | -100.0% | 12 | -76.5% | 0.00% | – |
| Q3 2017 | $2,716,000 | -12.6% | 51 | +2.0% | 0.00% | – |
| Q2 2017 | $3,106,000 | -98.7% | 50 | -98.6% | 0.00% | -100.0% |
| Q1 2017 | $236,552,000 | – | 3,490 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |